Haifa, Israel

Ravit Oren

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 10.8

ph-index = 1


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ravit Oren: Innovator in Cancer Therapeutics

Introduction

Ravit Oren is a notable inventor based in Haifa, Israel, recognized for his contributions to the field of cancer therapeutics. With a total of three patents to his name, Oren has made significant strides in developing innovative solutions for cancer treatment.

Latest Patents

Oren's latest patents include groundbreaking work on affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity. These compositions are designed to bind to specific cells, such as HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP, or HLA-A2/TyrD+ cells, making them valuable for diagnostics and therapy. Another significant patent involves antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA-restricted manner, specifically targeting HLA-A2/TyrD369-377. This innovation includes complementary determining region (CDR) sequences of heavy and light chain antibodies, along with methods for using these antibodies in cancer treatment.

Career Highlights

Throughout his career, Ravit Oren has worked with various companies, including Adicet Therapeutics, Inc. His work has focused on advancing the understanding and treatment of cancer through innovative therapeutic approaches.

Collaborations

Oren has collaborated with notable colleagues, including Mira Peled Kamar and Galit Denkberg, contributing to a dynamic research environment that fosters innovation.

Conclusion

Ravit Oren's work exemplifies the impact of innovative thinking in the field of cancer therapeutics. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…